GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » Cyclically Adjusted Price-to-FCF

DHR (Danaher) Cyclically Adjusted Price-to-FCF : 24.73 (As of Jun. 02, 2025)


View and export this data going back to 1978. Start your Free Trial

What is Danaher Cyclically Adjusted Price-to-FCF?

As of today (2025-06-02), Danaher's current share price is $189.90. Danaher's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $7.68. Danaher's Cyclically Adjusted Price-to-FCF for today is 24.73.

The historical rank and industry rank for Danaher's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

DHR' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 16.44   Med: 29.13   Max: 53.97
Current: 24.74

During the past years, Danaher's highest Cyclically Adjusted Price-to-FCF was 53.97. The lowest was 16.44. And the median was 29.13.

DHR's Cyclically Adjusted Price-to-FCF is ranked better than
53.03% of 66 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.69 vs DHR: 24.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Danaher's adjusted free cash flow per share data for the three months ended in Mar. 2025 was $1.462. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $7.68 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Danaher Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Danaher's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Danaher Cyclically Adjusted Price-to-FCF Chart

Danaher Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.77 49.53 34.88 32.18 30.58

Danaher Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.55 33.38 37.00 30.58 26.71

Competitive Comparison of Danaher's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Danaher's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Danaher's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Danaher's Cyclically Adjusted Price-to-FCF falls into.


;
;

Danaher Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Danaher's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=189.90/7.68
=24.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danaher's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Danaher's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.462/134.9266*134.9266
=1.462

Current CPI (Mar. 2025) = 134.9266.

Danaher Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 1.331 100.684 1.784
201509 1.223 100.392 1.644
201512 1.535 99.792 2.075
201603 0.933 100.470 1.253
201606 1.618 101.688 2.147
201609 0.955 101.861 1.265
201612 0.686 101.863 0.909
201703 0.569 102.862 0.746
201706 1.223 103.349 1.597
201709 1.322 104.136 1.713
201712 1.003 104.011 1.301
201803 0.974 105.290 1.248
201806 1.243 106.317 1.577
201809 1.083 106.507 1.372
201812 1.540 105.998 1.960
201903 0.784 107.251 0.986
201906 1.397 108.070 1.744
201909 1.102 108.329 1.373
201912 1.283 108.420 1.597
202003 0.969 108.902 1.201
202006 1.796 108.767 2.228
202009 2.121 109.815 2.606
202012 2.630 109.897 3.229
202103 2.204 111.754 2.661
202106 2.466 114.631 2.903
202109 2.360 115.734 2.751
202112 2.665 117.630 3.057
202203 2.329 121.301 2.591
202206 2.315 125.017 2.499
202209 2.350 125.227 2.532
202212 3.046 125.222 3.282
202303 2.280 127.348 2.416
202306 2.144 128.729 2.247
202309 1.767 129.860 1.836
202312 1.588 129.419 1.656
202403 1.934 131.776 1.980
202406 1.522 132.554 1.549
202409 1.666 133.029 1.690
202412 2.063 133.157 2.090
202503 1.462 134.927 1.462

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Danaher  (NYSE:DHR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Danaher Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Danaher's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Danaher Business Description

Address
2200 Pennsylvania Avenue, North West, Suite 800W, Washington, DC, USA, 20037-1701
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Executives
Steven M Rales director, officer: Chairman 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Alan G Spoon director 1150 15TH ST NW, WASHINGTON DC 20071
Brian W Ellis officer: Senior Vice President - GC 2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037
Daniel Raskas officer: VP-Corporate Development 2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Georgeann Couchara officer: SVP, Human Resources 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Linda Filler director 2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew officer: EVP & Chief Financial Officer 2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Rainer Blair officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr director DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Teri List director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jose-carlos Gutierrez-ramos officer: SVP, Chief Scientific Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Raymond C Stevens director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jennifer Honeycutt officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan director C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003